Objective: To investigate the clinical and prognostic value of SLC25A12 in patients with acute myeloid leukemia (AML).
Methods: The expression levels of SLC25A12 in bone marrow or peripheral blood cells of AML patients and healthy people in two independent cohorts (n=46, n=290, respectively) were compared. Then it was assessed that the prognostic value of SLC25A12 expression in two independent AML study cohorts (n=163, n=329, respectively) by mean of integrated analysis of genomic, transcriptome, clinical and prognosis information.
Results: The expression of SLC25A12 in AML patients significantly increased as compared with that of healthy people (P=0.0001, P=0.0238, respectively). Univariate and multivariate analyze showed that high SLC25A12 expression was significantly associated with shorter event-free survival (EFS)(HR=1.605, P=0.018) and overall survival (OS)(HR=1.818, P=0.002) of patients. In favorable-risk and intermediate-risk subgroups, patients with high SLC25A12 expression showed shorter EFS and OS than patients with low SLC25A12 expression.
Conclusion: High SLC25A12 expression significantly associated with poor prognosis of AML patients, which suggests that SLC25A12 aberrant expression can be used as a potential molecular marker for prognosis evaluation of AML patients.
题目: 基于多维度临床数据整合分析揭示SLC25A12表达水平在急性髓系白血病患者中的预后价值.
目的: 研究分析SLC25A12在急性髓系白血病(AML)患者中的临床和预后价值.
方法: 本研究分别在2个队列中（n=46； n=290）比较了SLC25A12基因在AML患者和健康人骨髓或外周血细胞中的表达水平，利用2个独立AML研究队列（n=163；n=329）的基因组、转录组、临床和预后等多维度信息进行整合，分析SLC25A12的预后价值.
结果: 在AML患者白血病细胞中，SLC25A12的表达量明显高于健康人（P=0.0001；P=0.0238），单因素和多因素预后分析证实，SLC25A12高表达与患者较短的无事件生存（EFS，HR=1.605，P=0.018）和总体生存（OS，HR=1.818，P=0.002）显著相关。这进一步证实在预后危险度为预后良好和预后中等两个亚组中，SLC25A12高表达的患者无事件生存和总体生存同样显著降低.
结论: SLC25A12高表达与AML患者的不良预后生存显著相关，这提示 SLC25A12异常表达可作为AML预后评估的潜在的分子标志物.